key: cord-0886873-jm5jblyt authors: Mercatelli, Daniele; Triboli, Luca; Fornasari, Eleonora; Ray, Forest; Giorgi, Federico M. title: Coronapp: A web application to annotate and monitor SARS‐CoV‐2 mutations date: 2020-12-01 journal: J Med Virol DOI: 10.1002/jmv.26678 sha: d9ffa109e3f9e1d803460a3e35a5d04d6581ae1b doc_id: 886873 cord_uid: jm5jblyt The avalanche of genomic data generated from the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus requires the development of tools to detect and monitor its mutations across the world. Here, we present a webtool, coronapp, dedicated to easily processing user‐provided SARS‐CoV‐2 genomic sequences and visualizing the current worldwide status of SARS‐CoV‐2 mutations. The webtool allows users to highlight mutations and categorize them by frequency, country, genomic location and effect on protein sequences, and to monitor their presence in the population over time. The tool is available at http://giorgilab.unibo.it/coronannotator/ for the annotation of user‐provided sequences. The full code is freely shared at https://github.com/federicogiorgi/giorgilab/tree/master/coronannotator. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel pathogenic enveloped RNA β-coronavirus causing a severe illness in human hosts known as coronavirus disease-2019 (COVID- 19) . The predominant COVID-19 illness is viral pneumonia, often requiring hospitalization and, in some cases, intensive care. 1 With almost 39 million laboratory-confirmed positive cases worldwide as of October 16, 2020 , and an estimated case fatality rate across 204 countries of 5.2%, COVID-19 has become a global health challenge in only a few months. 2 SARS-CoV-2 infection depends on the recognition of host angiotensin-converting enzyme 2 (ACE2), exposed on the cell surface in human lung tissues. 3, 4 SARS-CoV-2 spike glycoprotein binds ACE2, mediating membrane fusion and cell entry. 5 Upon cell entry, the virus subverts host cell molecular processes, inducing interferon responses and eventually apoptosis. 6 To date, much effort has been made to develop therapeutic strategies to limit SARS-CoV-2 transmission and replication, but no treatment or vaccine has proven effective against the virus, and repurposing of approved therapeutic agents has been the main practical approach to manage the emergency so far. 7 As viruses mutate during replication, the emergence of SARS-CoV-2 substrains and the challenge of a probable antigenic drift require attention, especially for vaccine development. 8 Although sequence analyses of SARS-CoV-2 have shown that genomic variability is very low, 9 new SARS-CoV-2 mutation hotspots are emerging due to the high number of infected individuals across countries and to viral replication rates. 10 Three major SARS-CoV-2 clades known as clade G, V, and S have emerged, showing a different geographical prevalence. 10 The Global Initiative on Sharing All Influenza Data (GISAID) has defined these clades according to the presence of a handful of specific and recurring mutations, highlighted in Table 1 . An alternative nomenclature, proposed by the pangolin project, 11 is also being used by the community as an alternative to the GISAID one (Table 1) . tropism or causing more aggressive symptoms. Constant and widespread monitoring of mutations is also a powerful means of informing drug development and global or local pandemic management. GISAID has collected to date (October 16, 2020) over 135,000 publicly accessible SARS-CoV-2 sequences. The GISAID effort has made it possible to compare genomes on a geographical and temporal scale and an increasing number of laboratories have started to sequence COVID-19 patient samples worldwide. 13, 14 Several online tools have been developed to monitor the evolution of the virus from a phylogenetic perspective, such as Nextstrain, 15 or to visualize epidemiological data, such as the number of cases and deaths. 16 However, no online tool currently exists to annotate userprovided SARS-CoV-2 genomic sequences, 17 which may derive from specific GISAID subsets or from sequencing efforts of individual laboratories; neither does any tool specifically monitor the prevalence of specific SARS-CoV-2 mutations associated with particular geographic regions or protein locations nor their frequency in the population over time. To overcome these limitations, we have developed coronapp, a web application with two purposes: real-time tracking of SARS-CoV-2 mutational status and annotation of user-provided viral genomic sequences. Our tool enables users to easily perform genomic comparisons and provides an instrument to monitor SARS-CoV-2 genomic variance, both worldwide and by uploading custom and locally produced genomic sequences. The webtool is available at http://giorgilab.unibo.it/coronannotator/ and the full source code is shared on GitHub https://github.com/federicogiorgi/giorgilab/tree/ master/coronannotator. The webtool coronapp has been developed using the programming language R and is based on a Shiny server (current version 1.4.0.2) running on R version 3.6.1. The app is based on two distinct files, server.R and ui.R, managing the server functionalities and the browser visualization processes, respectively. The results visualization utilizes both basic R functions and Shiny functionalities; for tooltip functionality, coronapp uses the R package googleVis v0.6.4, which provides an interface between R and the Google visualization API. 18 The core of the annotation of the user-provided sequences rests in the NUCMER (Nucleotide Mummer) alignment tool, version 3.1. 19 Nucmer output is processed by UNIX and R scripts provided in GitHub within the server.R file. The webtool coronapp is available at the website http://giorgilab. unibo.it/coronannotator/ and it allows the user to annotate SARS-CoV-2 sequences to identify mutations. The app also allows users to annotate user-provided sequences ( Figure 1A ). There are multiple functionalities of coronapp, described in the following paragraphs. A worldwide analysis is shown, generated using data from GISAID. Specifically, we processed all SARS-CoV-2 complete (>29,000 sequenced nucleotides) genomic sequences, excluding low-quality sequences (>5% undefined nucleotide "N") and viruses extracted from nonhuman hosts. The underlying database is updated weekly, and we provide the date of the last version as a reference for studies based on the data provided. We indicate the number of samples processed and the total number of mutational events detected ( Figure 1A ). We also show the number of distinct mutated loci. Currently, this number is slightly below 20,000, meaning that two-thirds of the original Wuhan SARS-CoV-2 genome has been affected by mutations and/or sequencing errors (the full length of the reference genome is 29,903 nucleotides, based on sequence id NC_045512.2). The sequence NC_045512.2 has been, since January 2020, the official NCBI/Re-fSeq SARS-CoV-2 genome reference. It was originally submitted by T A B L E 1 Current nomenclature of SARS-CoV-2 GISAID clades and pangolin lineages by specific mutations (named after genomic coordinate according to reference sequence NC_045512. We show the frequency of mutations along the length of every SARS-CoV-2 protein, reporting in the X axis the amino acid position and on the Y axis its frequency, either as the number of observed samples carrying the mutation, the base 10 logarithm of that number, or the percentage over all sequenced samples. In the example in Figure 1B the mutations appear to be evenly distributed in frequency along the protein length, with the most frequent mutation being the aforementioned D614G. Mouse-over functionality is provided to allow the user to identify the selected mutation (e.g., N439K in Figure 1B ). The user can visualize or download the full table of mutations on which the webtool operates ( Figure 2A ). This table is frequently updated and allows the user to specify a worldwide or a country-specific data set. The table also provides a Search function to look for specific variants or sample ids, and it can be viewed online or downloaded in full as a Comma-Separated The table shows every mutation in a specific geographical area, reporting: • The GISAID sample ID (useful for cross-reference with the GISAID database and other analyses based on it, e.g., Nextstrain). • The country where the sample was collected. • The position of the mutation, on the reference genome (refpos) and on the sample (qpos). • The sequence at the mutation site, on the reference genome (refvar) and on the sample (qvar). • The length of the sample genome (qlength); the reference genome is 29,903 nucleotides long. o Extragenic: a mutation affecting intergenic or UTR regions. • The extended annotation of the protein region affected by the mutation (e.g., "Spike" for "S" or "Predicted phosphoesterase, papain-like proteinase" for NSP3, the nonstructural protein 3). • The full name of the variant (varname), in the format proteinName:AApositionAA, to allow for a unique denomination of viral proteome variants. The user is also provided with a general overview of the mutational status of the selected country or the entire world ( Figure 2B ). Six bar plots provide a summary and highlights of the data set, specifically: • The most mutated samples, indicating which samples (in GISAID IDs) carry the highest number of mutations. • The overall mutations per sample, indicating the distributions of mutations per sample. It has been previously reported 10 that the current mode for mutation number compared to the reference NC_045512.2 genome is 7.5. • The most frequent events per class. Classes are the same as reported in the mutation table and are described in the previous paragraph. • The most frequent events per type. Individual mutation types are shown as specific nucleotides events, for example, cytosine to thymidine transitions (C>T), guanosine to thymidine transversion (G>T), or even multinucleotide mutations (e.g., GGG>AAC, observed in the nucleocapsid protein). As reported before, nucleotide transitions seem to be the most abundant SARS-CoV-2 type of mutational event worldwide. 12 • The most frequent events, either in nucleotide coordinates or in aminoacidic coordinates. Currently, the most frequent events are four mutations affecting SARS-CoV-2 genomes belonging to clade G, which is the most sequenced worldwide and predominant in Europe. These mutations are A23403G (associated with the already mentioned D614G mutation in the spike protein), C3037T, C14408T, and C241T. The coronapp webtool allows users to monitor the abundance and frequency of any SARS-CoV-2 mutation in any country specified ( Figure 3A ). Both plots in this section report continuous dates on the Coronapp provides the user with the possibility of uploading one or more SARS-CoV-2 genomic sequences, which can be complete or partial. The format of the sequences is standard FASTA, and an example input FASTA containing 12 sequences is provided ( Figure 3B ). Additionally, it enables scientists to perform mutational covariance analyses and to identify present and future significant functional interactions between viral mutations, as previously attempted for the influenza virus and the human immunodeficiency virus (HIV). 20 Another application is the identification of the most frequent mutations in specific protein regions: for example, our tool can quickly identify that the most frequent mutation in the spike protein, D614G, lies outside the known interaction domain with the human protein ACE2, which spans roughly between spike amino acids 330 and 530. 21 Scientists are currently debating on whether the increased frequency of D614G genomes 10 is the result of SARS-CoV-2 adaptation to the human host 22 or rather a mutation with no effective phenotype. 23 A recently published structural model simulating the effect of the D614G mutation on the 3D structure of the spike protein has suggested that this mutation may result in a viral particle, which binds ACE2 receptors less efficiently, due to the masking of the host receptor-binding site on viral spikes. 24 The same researchers have reported a possible correlation of the D614G form with increased case fatality rates, hypothesizing that this mutation may lead to a viral form which is better suited to escape immunologic surveillance by eliciting a lower immunologic response. 24 The coronapp analysis highlighted in Figure 1B shows that a mutation located within the spike/ACE2 interaction domain is the change of asparagine (N) to a lysine (K) in position 439 of the spike sequence; this mutation could affect the protein folding or its affinity with ACE2, as asparagine is less charged than the basic amino acid lysine. One of coronapp's key strengths is to help prioritize scientific efforts on specific aminoacidic variations that could affect the efficacy of antiviral strategies or the development of a vaccine by tracking the most frequent mutations in the population. A further novelty of coronapp is that it provides a means to assess the growth or decline of specific mutations over time to identify possible viral adaptation mechanisms. We provide not only the webtool but also all the underlying code for the annotation and visualization steps on a public GitHub repository, to help other computational scientists in the ongoing battle against COVID-19. Furthermore, the coronapp structure and concept could be expanded to other current and future pathogens as well (e.g., seasonal influenza or HIV), to monitor the mutational status across proteins, countries, and time. We thank the Italian Ministry of University and Research for their support (grant Montalcini 2016) and CINECA (grant HP10CC5F89). The authors declare that there are no conflict of interests. The data that support the findings of this study was generated by all the contributors of the GISAID consortium, available at https://www. gisaid.org/. ORCID Federico M. Giorgi https://orcid.org/0000-0002-7325-9908 Clinical characteristics of coronavirus disease 2019 in China Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Master regulator analysis of the SARS-CoV-2/human interactome Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Imbalanced host response to SARS-CoV-2 drives development of COVID-19 A review of SARS-CoV-2 and the ongoing clinical trials Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment Genomic variance of the 2019-nCoV coronavirus Geographic and genomic distribution of SARS-CoV-2 mutations A dynamic nomenclature proposal for SARS-CoV-2 to assist genomic epidemiology Comparative genomics suggests limited variability and similar evolutionary patterns between major clades of SARS-CoV-2 Spread of SARS-CoV-2 in the Icelandic Population Coast-to-coast spread of SARS-CoV-2 during the early epidemic in the United States Nextstrain: real-time tracking of pathogen evolution Coronavirus pandemic (COVID-19). Our World Data Web tools to fight pandemics: the COVID-19 experience Using the Google visualisation Using MUMmer to identify similar regions in large sequence sets Statistical characteristics of amino acid covariance as possible descriptors of viral genomic complexity Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate Coronapp: A web application to annotate and monitor SARS-CoV-2 mutations